Ascent Biomedical Ventures

Peerbridge Health is a mobile health IT company that seeks to bring independence and precision with remote monitoring capabilities for medical, wellness, and performance-based needs including the monitoring of vital signs, with thoughtful design and a seamless user experience. It has two digital health and fitness pioneering patents for medical-grade monitoring of all vital signs, with other patents pending. The company was founded by Angelo Acquista and is based in New York.

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

eCaring Home Care Software offers Home Care Agencies a SaaS solution for scheduling, delivering, and billing home care services. We also offer mobile apps with Electronic Visit Verification (EVV) to support the delivery of home care services and secure communications for nurses and caregivers.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.

Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

TargAnox develops drugs that help treat oncology and metabolic related inllnesses.

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Ouroboros, Inc. manufactures spine products for degenerated disc disease. The company is based in San Diego, California.

InnerPulse, Inc. develops technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias. It offers invasive treatment that enables physicians to implant the life-saving Percutaneous Implantable Cardioverter Defibrillator within the patient's vascular system. InnerPulse, Inc. was formerly known as Interventional Rhythm Management, Inc.

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.

Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Entigo specializes in enterprise warranty chain management solutions, providing businesses with tools to streamline warranty processing. Its primary offerings include Entigo Warranty, which facilitates the management of warranty claims, and Entigo Catalyst, designed for strategic assessments of existing warranty operations. The company also offers a range of services such as project management, implementation consulting, and systems integration. These solutions aim to automate the registration and claims process, reduce error rates, and enhance analytics for informed decision-making, ultimately improving product quality and minimizing warranty costs. Entigo's systems are tailored to meet the needs of Fortune 500 manufacturers across various sectors, including automotive, aerospace, and industrial equipment. Founded in 1995 and headquartered in Exton, Pennsylvania, Entigo is committed to optimizing warranty processes and ensuring seamless integration with warranty chain partners.